The Subcutaneous Drug Development & Delivery Consortium (SC Consortium) aims to collaboratively transform patient care and improve patient outcomes by leading fundamental advancements in the SC drug development and delivery space, in a precompetitive manner. The SC Consortium is led by leaders in the SC industry, who focus on driving forward activities and efforts that allow participating organizations to provide value to the entire SC ecosystem. You can visit the website to learn more about our ongoing efforts, from workshops to data-pooling to manuscript development, and more!” Our 2022 sub-team roadmaps are focused on 5 key areas fundamental to development of drug-device combination products: • High Dose / Large Volume SC Technology • Patient Preference and Experience • Bioavailability • Immunogenicity • Clinical Trial Strategy